BOSTON — In a unprecedented breakthrough for oncology, the pivotal RASolute-302 phase 3 clinical trial has demonstrated that the multi-selective RAS(ON) inhibitor daraxonrasib nearly doubles overall survival in patients with previously treated metastatic pancreatic cancer.

For decades, the KRAS protein was widely considered undruggable due to its smooth, featureless structure that resisted traditional small-molecule inhibitors. However, this landmark study, published in the New England Journal of Medicine and highlighted at the 2026 American Society of Clinical Oncology (ASCO) meeting, marks a definitive paradigm shift in the treatment of this recalcitrant disease.

Lead investigator Dr. Brian M. Wolpin emphasized the profound implications of these findings. By effectively turning off the mutated KRAS protein regardless of the specific variant, daraxonrasib halts cancer cell proliferation without the severe systemic toxicity often associated with conventional cytotoxic therapies. Treatment-related adverse events were notably lower in the daraxonrasib arm (10.8%) compared to the chemotherapy arm (18.7%).

This efficacious new therapeutic avenue is poised to ameliorate the historically grim prognosis of metastatic pancreatic cancer. As regulatory reviews progress, the medical community anticipates that daraxonrasib will soon become a cornerstone of second-line treatment protocols, offering renewed hope to thousands of patients worldwide.